Journal of the Society for Cardiovascular Angiography & Interventions最新文献

{"title":"Tricuspid Valve in Congenital Heart Disease Patients: A Triad of Problems and No Remedy in Sight","authors":"Zahid Amin MD , Niall Linnane MD","doi":"10.1016/j.jscai.2025.103805","DOIUrl":"10.1016/j.jscai.2025.103805","url":null,"abstract":"","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 8","pages":"Article 103805"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hold the Nitro: Acetylcholine Provocation Testing for Coronary Vasospasm","authors":"Adam S. Vohra MD, MBA , Eric A. Osborn MD, PhD","doi":"10.1016/j.jscai.2025.103760","DOIUrl":"10.1016/j.jscai.2025.103760","url":null,"abstract":"","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 8","pages":"Article 103760"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association of COVID-19 and Mortality in Hospitalizations With Coronary Artery Bypass Graft","authors":"Godfrey Tabowei MD ,&nbsp;John Garza PhD ,&nbsp;Ayman Fath MD ,&nbsp;Ahmed Bashir Sukhera MD ,&nbsp;Oboseh John Ogedegbe MD ,&nbsp;Gabriel Alugba MD ,&nbsp;Samuel Dadzie MD ,&nbsp;Ooreoluwa Fasola MD ,&nbsp;Meron Tesfaye MS ,&nbsp;Evbu Enakpene MD ,&nbsp;Anand Prasad MD","doi":"10.1016/j.jscai.2025.103605","DOIUrl":"10.1016/j.jscai.2025.103605","url":null,"abstract":"<div><h3>Background</h3><div>COVID-19 is associated with a higher burden of cardiovascular morbidity and mortality. The association of COVID-19 and mortality in hospitalizations with coronary artery bypass graft (CABG) has not been determined.</div></div><div><h3>Methods</h3><div>We conducted a population-based cohort study of the association of COVID-19 and mortality in hospitalizations with CABG using the Texas Inpatient Public Use Data File over the period Q2 2020 through Q4 2023. The primary exposure was a diagnosis of COVID-19, and the primary outcome was in-hospital mortality. Short-term mortality and total length of stay were used as secondary outcomes. The primary analysis approach was overlapping propensity score weighting with treatment weighting and inverse probability of treatment weighting applied as alternative analyses. Results are reported as adjusted risk ratio (aRR) and 95% CI. The adjusted risk difference and 95% CI are provided as an alternative effect size measure.</div></div><div><h3>Results</h3><div>A total of 47,501 hospitalizations with a procedure code for CABG were identified, of which 509 (1.1%) had COVID-19. CABG hospitalizations with vs without COVID-19 had higher comorbidity index (2.01 ± 1.65 vs 1.65 ± 1.61), more frequent need for invasive mechanical ventilation (12.8% vs 8.5%), had higher rates of myocardial infarction (65.0% vs 45.6%), higher rates of congestive heart failure (53.4% vs 40.1%), and higher rates of acute kidney injury (35.6% vs 24.3%); <em>P</em> &lt; .0001 for each comparison. CABG hospitalizations with COVID-19 had higher unadjusted in-hospital mortality (6.3% vs 2.2%) and unadjusted length of stay (16.2 ± 11.6 days vs 9.6 ± 6.8 days), compared with those without COVID-19. In adjusted analysis, COVID-19 was associated with a 53.9% increase in the risk of in-hospital mortality (aRR, 1.5394; 95% CI, 1.0836 to 2.1870) and a 40.3% increase in length of stay aRR 1.4028 (95% CI, 1.3138 to 1.4978).</div></div><div><h3>Conclusions</h3><div>COVID-19 was strongly associated with increased mortality in hospitalizations with CABG during the pandemic. The association weakened year over year and by 2023 was no longer present. COVID-19 has remained strongly associated with increased length of stay in hospitalizations with CABG including after the conclusion of the pandemic.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 8","pages":"Article 103605"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoking and Coronary Atherosclerosis: Disproportionate Impact on the Right Coronary Artery","authors":"Axel Dahlgren MD ,&nbsp;David Erlinge MD, PhD ,&nbsp;Ryo Torii PhD ,&nbsp;Enhui Yong MD ,&nbsp;Göran Bergström MD, PhD ,&nbsp;Tomas Jernberg MD, PhD ,&nbsp;Ole Fröbert MD, PhD ,&nbsp;Pernille G. Thrane MD, PhD ,&nbsp;Michael Mæng MD, PhD ,&nbsp;Gregg W. Stone MD, PhD ,&nbsp;Moman A. Mohammad MD, PhD","doi":"10.1016/j.jscai.2025.103609","DOIUrl":"10.1016/j.jscai.2025.103609","url":null,"abstract":"<div><h3>Background</h3><div>We aimed to study the long-term effect of smoking on coronary atherosclerosis progression at the segmental level.</div></div><div><h3>Methods</h3><div>Angiographic data (1989-2017) on current, former, and nonsmokers were collected from the Swedish Coronary Angiography and Angioplasty Registry. The Western Denmark Heart Registry was used to validate the results. Patients with clinically indicated angiography with ≥2 coronary arteries without obstructive coronary artery disease were included. The main outcome was segmental plaque progression, percutaneous coronary intervention, or coronary artery bypass grafting within 15 years.</div></div><div><h3>Results</h3><div>In total, 215,364 Swedish patients with 993,405 coronary arteries (left anterior descending artery [LAD], left circumflex artery [LCX], and right coronary artery [RCA]) were included. The validation cohort consisted of 19,613 patients. Per 1000 patient-years, plaque progression incidence rate was 11.3 (95% CI, 10.9-11.7) for smokers, 10.2 (95% CI, 9.9-10.5) for former smokers, and 7.7 (95% CI, 7.5-7.9) for nonsmokers. Smokers demonstrated higher relative risk of plaque progression in RCA (hazard ratio, 1.87; 95% CI, 1.73-2.03) vs LAD (hazard ratio, 1.21; 95% CI, 1.12-1.30). Swedish and Danish smokers with ST-segment elevation myocardial infarction had higher proportion of RCA as the culprit artery compared to nonsmokers (smokers: RCA, 42.4%; LAD, 42.0%; LCX, 15.6%; nonsmokers: RCA, 33.1%; LAD, 51.4%; LCX, 15.5%).</div></div><div><h3>Conclusions</h3><div>This observational cohort study identifies distinct differences in plaque progression patterns between smokers and nonsmokers, with smoking linked to increased plaque progression in the RCA, in contrast to the LAD in nonsmokers. These findings reemphasize the need for targeted smoking prevention and warrant further investigation into RCA-specific mechanisms of plaque progression and MI.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 8","pages":"Article 103609"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Tale of Two: 2-Year Outcomes of 2 Patients Undergoing Compassionate Use INTREPID and TricValve System Placement: Case Series","authors":"Hernan L. Vera-Sarmiento MD ,&nbsp;Tsuyoshi Kaneko MD ,&nbsp;Alan Zajarias MD","doi":"10.1016/j.jscai.2025.103705","DOIUrl":"10.1016/j.jscai.2025.103705","url":null,"abstract":"<div><div>Tricuspid regurgitation contributes to worsening heart failure symptoms, quality of life, and mortality. Medical therapy provides limited benefit, and surgical intervention in high-risk patients is associated with significant postoperative complications. Transcatheter tricuspid valve interventions are improving, but until recently, patient candidacy has been limited by the stringent inclusion and exclusion criteria of clinical trials. We present 2 cases of patients with severe tricuspid regurgitation treated in a compassionate use setting with transcatheter therapies. Patient 1 underwent TricValve (Products &amp; Features) placement for mitigation of right-sided heart failure with at least 24 months free of hospitalization. Patient 2 underwent compassionate INTREPID valve (Medtronic) placement with at least 24 months free of heart failure-related hospitalization.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 8","pages":"Article 103705"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SCAI Technical Review on Management of Chronic Venous Disease","authors":"Robert Attaran MD, FSCAI ,&nbsp;Matthew Edwards DO, FSCAI ,&nbsp;Matthew C. Bunte MD, FSCAI ,&nbsp;Yulanka Castro-Dominguez MD, FSCAI ,&nbsp;Eri Fukaya MD ,&nbsp;Karem Harth MD ,&nbsp;Pamela Kim MD ,&nbsp;Scott Firestone MS ,&nbsp;Emily Senerth MS, MPH ,&nbsp;Rebecca L. Morgan PhD, MPH","doi":"10.1016/j.jscai.2025.103730","DOIUrl":"10.1016/j.jscai.2025.103730","url":null,"abstract":"<div><h3>Background</h3><div>Chronic venous disease (CVD) impacts more than 25 million adults in the United States and is associated with a host of symptoms that can adversely affect quality of life (QoL), such as leg discomfort, edema, and ulceration. Treatments for CVD range from conservative therapy centered around use of compression to more invasive approaches, such as ablation, sclerotherapy, phlebectomy, venoplasty, and stenting.</div></div><div><h3>Methods</h3><div>A systematic review was conducted to address 8 questions on the management of CVD that were formulated by the Society for Cardiovascular Angiography &amp; Interventions (SCAI) Guideline Panel using the patient, intervention, comparator, outcome (PICO) format. Medical literature from January 1, 2008, through May 15, 2023, was searched using PubMed, Embase, and the Cochrane Central Register of Controlled Trials, except where an existing systematic review on compression therapy versus no intervention was updated with evidence from May 1, 2020, to May 15, 2023. Study selection was performed in duplicate; data extraction and risk of bias assessment were performed by 1 reviewer and reviewed by a second reviewer. Pooled effect estimates were calculated when applicable, and overall certainty in the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.</div></div><div><h3>Results</h3><div>Our combined searches identified 3648 titles and abstracts, of which 19 met eligibility criteria and informed the technical review. Studies reported on healing rate and time to healing, disease recurrence, symptom severity, and QoL among patients who were treated with compression therapy, ablation, sclerotherapy, phlebectomy, and venoplasty or stenting. Compression therapy probably results in slightly faster and more complete venous ulcer healing compared with no compression. Ablation of the great saphenous vein ± small saphenous vein may improve healing rate and symptoms over conservative therapy alone, particularly for ulcer disease. Evidence is very uncertain for any effect on healing rate, symptom score, QoL, and disease recurrence associated with perforator vein ablation, venoplasty, and stenting for iliocaval obstruction, sclerotherapy, and phlebectomy of symptomatic varicose veins.</div></div><div><h3>Conclusions</h3><div>Data from this technical review will inform the Society for Cardiovascular Angiography and Interventions Guideline on Management of Chronic Venous Disease. The panel also identified research priorities based on areas where evidence to guide clinical practice is lacking or very uncertain.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 8","pages":"Article 103730"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of Balloon Atrial Septostomy in Hybrid Stage 1 Palliation in Hypoplastic Left Heart Syndrome","authors":"William M. Fogarty IV DO ,&nbsp;Christina Phelps MD ,&nbsp;Mark Galantowicz MD ,&nbsp;Chance Alvarado MS ,&nbsp;Robin Alexander MS ,&nbsp;Arash Salavitabar MD ,&nbsp;Benjamin Blais MD ,&nbsp;Karen Texter MD ,&nbsp;Aimee K. Armstrong MD","doi":"10.1016/j.jscai.2025.103731","DOIUrl":"10.1016/j.jscai.2025.103731","url":null,"abstract":"<div><h3>Background</h3><div>The optimal timing of a balloon atrial septostomy (BAS) in patients with hypoplastic left heart syndrome (HLHS) undergoing hybrid stage 1 (HS1) palliation is unknown. We hypothesized that concomitant completion of the BAS and HS1 would decrease hospital stay, increase intensive care unit–free days, improve hemodynamic markers, and increase transplant-free survival.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed HLHS patients palliated with HS1 from January 2009 to July 2022 at our center. We excluded other single ventricle variants, those who did not have a BAS or had a BAS performed prior to the HS1, and those with an initial atrial septal intervention other than BAS. Patients were divided into 2 groups: (1) those with same-day BAS and HS1, and (2) BAS performed ≥1 day after the HS1.</div></div><div><h3>Results</h3><div>Twenty patients had a BAS and HS1 on the same day, and 69 patients had delayed BAS, whereas 29 patients were excluded. The same-day cohort had significantly shorter hospital length of stay, higher recorded cerebral near infrared spectroscopy troughs, and lower 30-day post-BAS/discharge brain natriuretic peptide levels. There was no difference in transplant-free survival, and a greater proportion of the same-day group required atrial septal reintervention.</div></div><div><h3>Conclusions</h3><div>Although there was no difference in transplant-free survival and higher rates of atrial septal reintervention, concomitant completion of BAS and HS1 in HLHS patients demonstrated shorter HS1 hospitalization and improved hemodynamic markers.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 8","pages":"Article 103731"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous-Only Approach for Transcatheter Patent Ductus Arteriosus Closure in Infants: Is It Time for Change?","authors":"Shyam C. Harinarayanan MD ,&nbsp;Stephan Wu MD ,&nbsp;Yousef Arar MD ,&nbsp;Thomas M. Zellers MD ,&nbsp;Surendranath R. Veeram Reddy MD ,&nbsp;Abhay A. Divekar MD","doi":"10.1016/j.jscai.2025.103735","DOIUrl":"10.1016/j.jscai.2025.103735","url":null,"abstract":"<div><h3>Background</h3><div>The standard approach for transcatheter closure of patent ductus arteriosus (TC-PDA) requires arterial access and is associated with the risk of arterial injury, a metric tracked by national quality improvement registries. Venous-only TC-PDA in premature infants is performed successfully without arterial access. It was hypothesized that PDA closure in infants could be performed safely and effectively without arterial access.</div></div><div><h3>Methods</h3><div>This is a single-center, retrospective, institutional review board–approved study. All infants weighing 2 to 10 kg who underwent TC-PDA closure between January 2019 and December 2024 were included in the study. Patients who underwent concurrent procedures and those with complex heart disease were excluded from the study. TC-PDA was performed using the standard approach or venous-only approach at the discretion of the attending cardiologist.</div></div><div><h3>Results</h3><div>In total, 150 patients underwent TC-PDA: 59 patients (19 male) underwent closure using the standard approach and 91 patients (35 male) using the venous-only approach. There was no difference in the minimum patent ductus arteriosus diameter. There was no pulse loss in the venous-only cohort; 1 patient (1.7%) treated with the standard approach had clinical symptomatic arterial injury requiring therapy. The venous-only cohort was younger, weighed less, and had lower radiation exposure, contrast use, shorter total procedure, and total sheath time. There was no difference in other adverse procedural outcomes.</div></div><div><h3>Conclusions</h3><div>Venous-only approach for TC-PDA closure in infants is as effective and efficient as the standard approach. The added advantage of eliminating arterial injury increases the safety for TC-PDA in small infants.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 8","pages":"Article 103735"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Same-Day Discharge After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes: A Pilot Study","authors":"Attilio Galhardo MD, MSc ,&nbsp;Siddhartha Mengi MD ,&nbsp;Vitor S. Netto MD ,&nbsp;Renato D. Lopes MD, PhD ,&nbsp;Adriano Caixeta MD, PhD","doi":"10.1016/j.jscai.2025.103728","DOIUrl":"10.1016/j.jscai.2025.103728","url":null,"abstract":"","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 8","pages":"Article 103728"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal Trends in Outcomes of Nonelective Versus Elective Transcatheter Edge-to-Edge Repair of the Mitral Valve","authors":"Muddasir Ashraf MD ,&nbsp;Suhail Q. Allaqaband MD ,&nbsp;Khawaja Afzal Ammar MD ,&nbsp;Renuka Jain MD ,&nbsp;Daniel R. Harland MD ,&nbsp;Haroon Zubair MD ,&nbsp;Charnai Sherry PA ,&nbsp;Tanvir Bajwa MD","doi":"10.1016/j.jscai.2025.103785","DOIUrl":"10.1016/j.jscai.2025.103785","url":null,"abstract":"<div><h3>Background</h3><div>Data are limited on outcomes of elective vs nonelective mitral transcatheter edge-to-edge repair (M-TEER).</div></div><div><h3>Methods</h3><div>Using the National Inpatient Sample, all adult patients who had M-TEER from 2013-2020 were included in the study. Univariate and multivariate linear and logistic regression were used to evaluate outcomes.</div></div><div><h3>Results</h3><div>Of 43,920 patients who underwent M-TEER, with a mean age (SE) of 77 (0.13) years, 46% were women. Of these, 23% were nonelective, and 77% were elective cases. Whites were more likely to have elective, and African Americans and Hispanics were more likely to have nonelective M-TEER. In-hospital mortality and resource utilization decreased over time in elective cases, but no significant change was seen in nonelective cases. Risk-adjusted odds of in-hospital mortality were higher in nonelective vs elective cases (adjusted odds ratio, 2.85; <em>P</em> &lt; .001). Risk-adjusted length of stay was also higher in nonelective vs elective cases (adjusted beta-coefficient, 7.16; <em>P</em> &lt; .001). Finally, the risk-adjusted inflation-adjusted cost was also higher in nonelective vs elective cases (adjusted beta-coefficient, 23,673; <em>P</em> &lt; .001).</div></div><div><h3>Conclusions</h3><div>Nonelective M-TEER is associated with poor outcomes. Hence, these patients should be treated in a timely fashion and should not be deferred if they meet the criteria for M-TEER. Rapid up-titration of guideline-directed medical therapy should be considered in patients with moderate to severe secondary mitral regurgitation to avoid an emergent need for transcatheter edge-to-edge repair and associated poor outcomes.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 8","pages":"Article 103785"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}